Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

30,447 signal articles · 144 in last 24h · 154,069 total before filter · latest 27m ago

144last 24h

877last 7d

146● bullish (7d)

99● bearish (7d)

214publishers

All Macro208 Earnings108 M&A125 Regulatory22 Product21 Analyst17

✕ clear all filtersticker: TEMSentiment:bullish neutral bearish ✓ showing all (incl. clickbait)

The Fly22d agoneutral

Sirius XM upgraded, Toast downgraded: Wall Street's top analyst calls

AFRM DKNG GTLB KLAR NIO TEM TOST XYZ

The Fly23d agobullish

Robinhood upgraded, Uber initiated: Wall Street's top analyst calls

ABNB DASH DUOL HOOD LYFT TEM TKR UBER

Motley Fool59d agobullish

Cathie Wood's Ark Bought $21.3 Million of SpaceX Stock as Shares Fell 45% From Their Record High. Wall Street's Median Price Target Is $243.81, 111.5% Above the Current Close.

Cathie Wood's investment fund is heavily invested in SpaceX stock.

CRSP NVDA SPCX TEM TSLA

Insider Monkey114d agobullish

H.C. Wainwright Maintains Buy Rating on Tempus AI (TEM) Following Strong Revenue Growth

Tempus AI, Inc. (NASDAQ:TEM) ranks among the best short squeeze stocks to invest in. Following the company’s first-quarter results, H.C. Wainwright reduced its price target for Tempus AI, Inc. (NASDAQ:TEM) to $64 from $95 while retaining a Buy rating on the company’s shares. Tempus AI, Inc. (NASDAQ:TEM) posted total revenue of $348.1 million in Q1, […]

GILD MRK TEM

Simply Wall St.115d agobullish

Tempus AI (TEM) Is Up 9.3% After New FDA-Cleared CDx And AI Oncology Platform Upgrades

In recent days, Tempus AI announced a string of oncology-focused product advances, including FDA approval of its xT CDx tumor-only sequencing assay, major upgrades to its AI-enabled Next and Hub platforms, and new tools like Preview, Lens, and the ArteraAI Prostate Test (mHSPC) that deepen its role in precision cancer care. Taken together, these moves highlight Tempus AI’s effort to turn its multimodal data and foundation models into end-to-end clinical and biopharma solutions, from faster...

TEM